Model Analysis of the Concentration-Dependent Permeability of P-gp Substrates-Reference-Cited by-同舟云学术

Model Analysis of the Concentration-Dependent Permeability of P-gp Substrates

Published:2010-02-05 Issue:3 Volume:27 Page:442-446
ISSN:0724-8741
Container-title:Pharmaceutical Research
language:en
Short-container-title:Pharm Res

Author:

Tachibana Tatsuhiko,Kitamura Satoshi,Kato Motohiro,Mitsui Tetsuya,Shirasaka Yoshiyuki,Yamashita Shinji,Sugiyama Yuichi

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology

Link

http://link.springer.com/content/pdf/10.1007/s11095-009-0026-9.pdf

Reference15 articles.

1. Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. Impact of drug transporter studies on drug discovery and development. Pharmacol Rev. 2003;55:425–61.

2. Fromm MF. Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest. 2003;33 Suppl 2:6–9.

3. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci. 2004;25:423–9.

4. Brinkmann U. Functional polymorphisms of the human multidrug resistance (MDR1) gene: correlation with P glycoprotein expression and activity in vivo. Novartis Found Symp. 2002;243:207–10. discussion 210-2, 231-5.

5. Fromm MF. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther. 2000;38:69–74.

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physiologically based in vitro – in vivo correlation of modified release oral formulations with non-linear intestinal absorption: A case study using mirabegron;European Journal of Pharmaceutics and Biopharmaceutics;2024-11

2. Reliability of in vitro data for the mechanistic prediction of brain extracellular fluid pharmacokinetics of P-glycoprotein substrates in vivo; are we scaling correctly?;2024-08-14

3. Interlaboratory Variability in the Madin–Darby Canine Kidney Cell Proteome;Molecular Pharmaceutics;2023-06-07

4. Translatability of in vitro Inhibition Potency to in vivo P-Glycoprotein Mediated Drug Interaction Risk;Journal of Pharmaceutical Sciences;2023-06

5. Physiologically‐based pharmacokinetic pharmacodynamic parent‐metabolite model of edoxaban to predict drug–drug‐disease interactions: M4 contribution;CPT: Pharmacometrics & Systems Pharmacology;2023-05-19